Department of Neurosurgery and Pituitary Tumor Center, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Front Endocrinol (Lausanne). 2022 Aug 19;13:947085. doi: 10.3389/fendo.2022.947085. eCollection 2022.
We aimed to perform a retrospective analysis of a rare subtype of corticotroph adenoma, Crooke's cell adenoma, to better understand its clinical features.
We collected -positive pituitary adenomas and screened Crooke's cell adenomas from January 2020 to December 2021 in our center. Case reports of such tumors were also collected through a literature search. Clinical data such as biochemical tests, imaging examinations, and pathological data of the above cases were analyzed.
A total of 101 -positive patients were treated in our center in the last 2 years, and 4 were finally pathologically diagnosed with Crooke's cell adenomas. All of these patients were male with elevated adrenocorticotropic hormone levels, and 50.0% presented with hypercortisolemia, Cushing's syndrome, visual impairment, and headache. The tumor diameter was significantly larger in these 4 patients (37.0 mm) than in the other patients (26.0 mm), and their tumor invasive behavior was more pronounced. Cases reported in the literature were mainly female (72.8%), and the clinical presentation was also dominated by Cushing's syndrome (65.1%) and hormonal dysfunction. Tumors were more common as macroadenomas (33.2 mm) and suprasellar growths (63.8%). The tumor recurrence rate was as high as 55.6%, with 6 cases progressing to pituitary carcinomas and 7.7% of tumor-related deaths. Our further integrated analysis of our center and reported cases revealed that gender, Cushing's syndrome, visual dysfunction, hormonal disorders, and tumor growth characteristics were statistically different in different tumor categories.
Crooke's cell adenoma is a tumor subtype with obvious clinical aggressive behavior, and an in-depth analysis of its clinical characteristics may assist in developing a comprehensive treatment plan.
本研究旨在对一种罕见的促肾上腺皮质激素细胞腺瘤(Crooke 细胞腺瘤)进行回顾性分析,以更好地了解其临床特征。
本研究于 2020 年 1 月至 2021 年 12 月在本中心收集了促肾上腺皮质激素阳性的垂体腺瘤,并对 Crooke 细胞腺瘤进行了筛查。同时还通过文献检索收集了此类肿瘤的病例报告。分析了上述病例的临床资料,包括生化检查、影像学检查和病理数据。
在过去的 2 年中,本中心共治疗了 101 例促肾上腺皮质激素阳性患者,最终有 4 例病理诊断为 Crooke 细胞腺瘤。这 4 例患者均为男性,促肾上腺皮质激素水平升高,50.0%的患者出现皮质醇增多症、库欣综合征、视力障碍和头痛。这 4 例患者的肿瘤直径(37.0mm)明显大于其他患者(26.0mm),且肿瘤侵袭性较强。文献报道的病例主要为女性(72.8%),临床表现也以库欣综合征(65.1%)和激素功能障碍为主。肿瘤多为大腺瘤(33.2mm)和鞍上生长(63.8%)。肿瘤复发率高达 55.6%,其中 6 例进展为垂体癌,7.7%的患者因肿瘤相关死亡。本研究进一步对本中心和文献报道的病例进行综合分析,结果显示不同肿瘤类型在性别、库欣综合征、视力障碍、激素紊乱和肿瘤生长特征方面存在统计学差异。
Crooke 细胞腺瘤是一种具有明显临床侵袭性行为的肿瘤亚型,深入分析其临床特征可能有助于制定全面的治疗方案。